Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chava Perry

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|July 1, 2021
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myelomaIrit Avivi, Roi Balaban, Tamir Shragai, et al.
Haematologica|July 8, 2021
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort studyRon Ram, Sigal Grisariu, Liat Shargian-Alon, et al.
Leukemia & Lymphoma|September 14, 2017
Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?Ohad S Bentur, Ronit Gurion, Anat Gafter-Gvili, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 20, 2022
The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patientsEsther Saiag, Ayelet Grupper, Irit Avivi, et al.
Transplantation and Cellular Therapy|July 2, 2021
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort StudyRon Ram, David Hagin, Nino Kikozashvilli, et al.
European Journal of Haematology|March 25, 2023
Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter studyOfrat Beyar Katz, Chava Perry, Sigal Grisariu-Greenzaid, et al.
Leukemia & Lymphoma|September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experienceYafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.
Transplantation and Cellular Therapy|October 13, 2024
Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional StudyRon Ram, Odelia Amit, Chava Perry, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|November 9, 2023
Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effectsSuzy E Meijer, Ora Halutz, Amos Adler, et al.
British Journal of Haematology|July 14, 2026
Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective studyTzvika Porges, Tsofia Levi, Eldad J Dann, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|July 1, 2021
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myelomaIrit Avivi, Roi Balaban, Tamir Shragai, et al.
Haematologica|July 8, 2021
Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort studyRon Ram, Sigal Grisariu, Liat Shargian-Alon, et al.
Leukemia & Lymphoma|September 14, 2017
Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?Ohad S Bentur, Ronit Gurion, Anat Gafter-Gvili, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 20, 2022
The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patientsEsther Saiag, Ayelet Grupper, Irit Avivi, et al.
Transplantation and Cellular Therapy|July 2, 2021
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort StudyRon Ram, David Hagin, Nino Kikozashvilli, et al.
European Journal of Haematology|March 25, 2023
Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter studyOfrat Beyar Katz, Chava Perry, Sigal Grisariu-Greenzaid, et al.
Leukemia & Lymphoma|September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experienceYafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.
Transplantation and Cellular Therapy|October 13, 2024
Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional StudyRon Ram, Odelia Amit, Chava Perry, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|November 9, 2023
Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effectsSuzy E Meijer, Ora Halutz, Amos Adler, et al.
British Journal of Haematology|July 14, 2026
Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective studyTzvika Porges, Tsofia Levi, Eldad J Dann, et al.
Pageof 8